Pacira Pharma signs global licensing deal with Aratana Therapeutics
Pacira Pharmaceuticals, Inc has signed a global licensing agreement with Aratana Therapeutics to develop and commercialise bupivacine liposome injectable suspension for animal health indications.
As per the deal, Aratana will develop and seek approval for the use of the product in veterinary surgery to manage post surgical pain, focusing initially on developing the product for cats, dogs and other companion animals.
The Bupivacine liposome suspension is approved for human use in the U.S. to manage the post surgical pain and is presently marketed by Pacira under the name Exparel.
Exparel is a non-opiod local anesthetic, which was approved by the U.S. Food and Drug Administration in October 2011 for administration into the surgical site to produce postsurgical analgesia.
Steven St. Peter, MD. CEO of Aratana Therapeutics said, “Given the rapid and widespread implementation of EXPAREL by surgeons performing human procedures, we are confident that adoption of this innovative product by veterinary surgeons will be equally impressive. The global companion animal health market remains significantly underserved despite the more than 150 million companion animals in the U.S.- many of whom will undergo surgical procedures. We believe this product fits nicely into our growing portfolio of companion animal therapeutics and will be welcomed by veterinarians committed to providing their patients with the best care available.”
As per the deal, Aratana made a one-time payment to Pacira of $1 million and will pay additional development and commercial milestones totaling up to $42.5 million.
On approval, the product by the FDA, Aratana will pay Pacira, a double-digit royalty on net sales of the product.
Pacira Pharmaceuticals is a well known specialty pharmaceutical company that is focused on clinical and commercial development of new products that meets the needs of acute care practioners and their patients. Aratana Therapeutics is a biopharmaceutical company that delivers high quality new medicines that addresses the significant therapeutic needs for dogs and cats.
NHS trials test that predicts sepsis 3 days in advance
A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England.
Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year.
The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time.
From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.
Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction.
Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.
The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years.
If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.
Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”